CanSino Biologics Inc. said it received Chinese regulatory approval to start human trials of a vaccine against the novel coronavirus, another example of a potential weapon against the illness being fast-tracked for testing as the global death toll escalates and nations impose lockdowns on their citizens.
The vaccine, co-developed by the Hong Kong-listed company and China’s Academy of Military Medical Sciences, will undergo clinical trials in Wuhan, CanSino Biologics said in a statement to the Hong Kong Stock Exchange on Wednesday. Wuhan is the epicenter for the pandemic that has spread to all corners of the planet, infecting more than ...
